Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks

Summary

Blood coagulation cascades can be activated by different mechanisms and to different levels in cancer patients. In a study conducted on the transcriptional profile of epithelial ovarian cancer patients a number of possible links between coagulation and inflammation have been suggested and we and others have reported that, in addition to its central role in blood coagulation and haemostasis, thrombin is a powerful regulator of inflammatory responses. Here, we report that thrombin-like activities were present in the malignant ascites of patients with ovarian carcinoma. Malignant ascites significantly enhanced the release of cytokines/chemokines, which have been previously shown to support tumour progression, such as interleukin (IL)-6, IL-1β, CCL2 and CXCL8, in human peripheral blood mononuclear cells of healthy volunteers. Interestingly, ascites enhanced the release of the anti-inflammatory cytokine IL-10 and inhibited the production of interferon-γ and IL-12. The presence of the anticoagulant antithrombin reversed IL-12 inhibition induced by ascites in human monocytes. Finally, the use of thrombin and of the specific thrombin receptor (PAR) agonist peptides, TFLLRN and AYGPK, suggests that IL-12 inhibition is thrombin-specific and related to PAR-1, but not to PAR-4. These findings underline the tight relationship between the coagulation pathway, where thrombin is the key enzyme, and cytokine modulation, including IL-12 inhibition, which is a critical feature of the tumour microenvironment, and may represent a powerful strategy used by tumours to escape immune surveillance.

Keywords

Thrombin - cytokines - inflammation - coagulation - tumour microenvironment

• References

• 1 Rak J, Yu JL, Luyendyk J. et al. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res 2006; 66: 10643-10646.
• 2 Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
• 3 Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-217.
• 4 Mehrad B, Keane MP, Strieter RM. Chemokines as mediators of angiogenesis. Thromb Haemost 2007; 97: 755-762.
• 5 Sica A, Saccani A, Bottazzi B. et al. Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. J Immunol 2000; 164: 762-767.
• 6 Chen D, Dorling A. Critical roles for thrombin in acute and chronic inflammation. J Thromb Haemost 2009; 7 (Suppl. 01) 122-126.
• 7 Coughlin SR, Camerer E. PARticipation in inflammation. J Clin Invest 2003; 111: 25-27.
• 8 Naldini A, Carney DH, Bocci V. et al. Thrombin enhances T cell proliferative responses and cytokine production. Cell Immunol 1993; 147: 367-377.
• 9 Colognato R, Slupsky JR, Jendrach M. et al. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 2003; 102: 2645-2652.
• 10 Colotta F, Sciacca FL, Sironi M. et al. Expression of monocyte chemotactic protein-1 by monocytes and endothelial cells exposed to thrombin. Amer J Pathol 1994; 144: 975-985.
• 11 Bar-Shavit R, Kahn A, Fenton JWI. et al. Chemotactic response of monocytes to thrombin. J Cell Biol 1983; 96: 282-285.
• 12 Tsopanoglou NE, Maragoudakis ME. Role of thrombin in angiogenesis and tumor progression. Semin Thromb Hemost 2004; 30: 63-69.
• 13 Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006; 10: 355-362.
• 14 Silini A, Ghilardi C, Ardinghi C. et al. Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clin Exp Metastasis 2010; 27: 43-53.
• 15 Zacharski LR, Wojtukiewicz MZ, Costantini V. et al. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Thromb Hemost 1992; 18: 104-116.
• 16 Grisaru-Granovsky S, Salah Z, Maoz M. et al. Differential expression of protease activated receptor 1 (Par1) and pY397FAK in benign and malignant human ovarian tissue samples. Int J Cancer 2005; 113: 372-378.
• 17 Wang X, Wang E, Kavanagh JJ. et al. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 2005; 3: 25.
• 18 Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351: 2519-2529.
• 19 Giuntoli RL, Webb TJ, Zoso A. et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009; 29: 2875-2884.
• 20 Naldini A, Aarden L, Pucci A. et al. Inhibition of interleukin-12 expression by {alpha}-thrombin in human peripheral blood mononuclear cells: a potential mechanism for modulating Th1/Th2 responses. Br J Pharmacol 2003; 140: 980-986.
• 21 Naldini A, Bernini C, Pucci A. et al. Thrombin-mediated IL-10 up-regulation involves protease-activated receptor (PAR)-1 expression in human mononuclear leukocytes. J Leukoc Biol 2005; 78: 736-744.
• 22 Spentzos D, Levine DA, Ramoni MF. et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004; 22: 4700-4710.
• 23 Schutyser E, Struyf S, Proost P. et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002; 277: 24584-24593.
• 24 Ramjee MK. The use of fluorogenic substrates to monitor thrombin generation for the analysis of plasma and whole blood coagulation. Anal Biochem 2000; 277: 11-18.
• 25 Butenas S, van't Veer C, Mann KG. „Normal” thrombin generation. Blood 1999; 94: 2169-2178.
• 26 Naldini A, Leali D, Pucci A. et al. Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. J Immunol 2006; 177: 4267-4270.
• 27 Peri G, Milanese C, Matteucci C. et al. A new monoclonal antibody (5D3-F7) which recognizes human monocyte-chemotactic protein-1 but not related chemokines. Development of a sandwich ELISA and in situ detection of producing cells. J Immunol Methods 1994; 174: 249-257.
• 28 Vandesompele J, De PK, Pattyn F. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: 1-12.
• 29 Fenton II JW.. Thrombin. Ann N Y Acad Sci 1986; 485: 5-15.
• 30 Gieseler F, Luhr I, Kunze T. et al. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy. Thromb Haemost 2007; 97: 1023-1030.
• 31 Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately?. Blood 2009; 114: 2367-2374.
• 32 Johnson K, Aarden L, Choi Y. et al. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 1996; 87: 5051-5060.
• 33 Loercher AE, Nash MA, Kavanagh JJ. et al. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999; 163: 6251-6260.
• 34 Naldini A, Morena E, Filippi I. et al. Thrombin inhibits IFN-gamma production in human peripheral blood mononuclear cells by promoting a Th2 profile. J Interferon Cytokine Res 2006; 26: 793-799.
• 35 Yin YJ, Salah Z, Grisaru-Granovsky S. et al. Human protease-activated receptor 1 expression in malignant epithelia: a role in invasiveness. Arterioscler Thromb Vasc Biol 2003; 23: 940-944.
• 36 VanDeWater L, Tracy PB, Aronson D. et al. Tumor cell generation of thrombin via functional prothrombinase assembly. Cancer Res 1985; 45: 5521-5525.
• 37 Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost 2008; 34: 154-160.
• 38 Traby L, Kaider A, Schmid R. et al. The effects of low-molecular-weight heparin at two different dosages on thrombin generation in cancer patients. A randomised controlled trial. Thromb Haemost 2010; 104: 92-99.
• 39 Nieman MT, LaRusch G, Fang C. et al. Oral thrombostatin FM19 inhibits prostate cancer. Thromb Haemost 2010; 104: 1044-1048.
• 40 Chopra V. V, Dinh TV, Hannigan EV. Angiogenin, Interleukins, and Growth-Factor Levels in Serum of Patients with Ovarian Cancer: Correlation with Angiogenesis. Cancer J Sci Am 1996; 2: 279.
• 41 Manenti L, Paganoni P, Floriani I. et al. Expression levels of vascular endothelial growth factor, matrix metallo-proteinases 2 and 9 and tissue inhibitor of metallo-proteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur J Cancer 2003; 39: 1948-1956.
• 42 Duluc D, Delneste Y, Tan F. et al. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood 2007; 110: 4319-4330.
• 43 Salah Z, Maoz M, Pokroy E. et al. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Mol Cancer Res 2007; 5: 229-240.
• 44 Naldini A, Filippi I, Ardinghi C. et al. Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. Eur J Cancer 2009; 45: 454-460.
• 45 Sica A, Saccani A, Bottazzi B. et al. Defective expression of the monocyte chemotactic protein-1 receptor CCR2 in macrophages associated with human ovarian carcinoma. J Immunol 2000; 164: 733-738.
• 46 Niers TM, Bruggemann LW, Klerk CP. et al. Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. Clin Exp Metastasis 2009; 26: 171-178.